News

January 12, 2017

Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza

Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza

With the news today that the first-ever patient has received the first commercial Spinraza dose, we are releasing an updated version of our SMA drug pipeline. This new version reflects the approval of Spinraza, as well as the true start of a key stage to ensure that more and more patients are...

READ MORE   |  

Topics: Community & Awareness, Advocacy, Front Page News

January 9, 2017

SMA Patient-Focused Drug Development Meeting with FDA Set for April 18, 2017

SMA Patient-Focused Drug Development Meeting with FDA Set for April 18, 2017

Tuesday, April 18, 2017, has been announced as the date for the SMA Patient-Focused Drug Development Meeting with the FDA.

At the Patient Focused Drug Development (PFDD) Meeting, individuals and families from throughout our community will have the opportunity to share their stories...

READ MORE   |  

Topics: Community & Awareness, Advocacy, Front Page News

December 29, 2016

Join Us for an Upcoming Webcast about SPINRAZA TM (nusinersen)

Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the U.S. for the treatment of Spinal Muscular Atrophy (SMA) in pediatric and adult patients. In order to receive an update on SPINRAZA, please join this webcast, which is intended...

READ MORE   |  

Topics: Community & Awareness, Clinical Trials, Advocacy, Front Page News

Items 1 - 3 of 48  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software